# **BMJ Open** Enhanced impact of psoriasis severity on the treatment demands of patients during the COVID-19 pandemic: a crosssectional study based on a national psoriasis registry in China

Zhihui Yang <sup>(D)</sup>, <sup>1</sup> Yu Jin <sup>(D)</sup>, <sup>2</sup> Mingyue Wang, <sup>1</sup> Ruoyu Li, <sup>1</sup> Wen-Qing Li <sup>(D)</sup>, <sup>2</sup> Hang Li<sup>1,3</sup>

**Objectives** The personalised treatment demands of patients with psoriasis did not get significant attention during the pandemic lockdown. This study aimed to investigate the treatment demands of patients with psoriasis with different severities, stratified by COVID-19 pandemic conditions.

Design Cross-sectional study design.

Setting Multicentre study based on a national psoriasis registry in China.

Participants A total of 22425 adult patients with psoriasis were enrolled between August 2020 and September 2021.

Primary and secondary outcome measures The primary outcomes were patient demands for guick healing of skin lesions and improving mental health, which were collected by questionnaires. Multivariable logistic models were used to examine the impact of disease severity, as measured by Psoriasis Area and Severity Index (PASI), body surface area (BSA) and Investigator's Global Assessment (IGA), on treatment demands, as stratified by COVID-19 pandemic conditions (lockdown vs non-lockdown).

**Results** Increasing PASI score significantly increased patient demands for rapid healing of skin lesions and improving mental health during non-lockdown periods. The magnitude of both associations further increased during the COVID-19 lockdown from an OR of 1.45 (95% CI 1.27 to 1.65) to 2.19 (95% Cl 1.57 to 3.05) and 2.21 (95% Cl 2.03 to 2.40) to 2.82 (95% Cl 2.24 to 3.55), respectively. The skin lesion healing demand was more triggered by the overall irritation level (measured by IGA, OR 1.64, 95% CI 1.35 to 1.99 during non-lockdown periods vs OR 2.70, 95% Cl 1.63 to 4.49 during lockdowns), while the mental health improving demand was more triggered by lesion coverage (measured by BSA, OR 2.01, 95% CI 1.85 to 2.19 vs OR 3.27, 95% Cl 2.57 to 4.15).

**Conclusions** Psoriasis aggravation significantly increased patients' treatment demands, especially during lockdowns. The used psoriasis severity measures highlighted patients' treatment demands differently. This suggests more accessible and personalised healthcare for patients with psoriasis should be available during future pandemics.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- $\Rightarrow$  This is, to date, the largest study investigating the association between psoriasis severity and treatment demands from the patients' perspective, and the first study comparing the aforementioned association between a lockdown and a non-lockdown period.
- $\Rightarrow$  Disease severity was assessed with different measures and from different aspects, making the results comprehensive and robust.
- $\Rightarrow$  Subjects who participated in our programme were enrolled from specific dermatological clinics, and thus may not represent the general psoriasis population.
- $\Rightarrow$  The demand for improving mental health was collected as a binary variable without professional psychological assessment.

## **INTRODUCTION**

Psoriasis is a chronic, non-fatal disease primarily affecting the skin. The prevalence of psoriasis varies geographically, with 0.14% and 1.99% of the population in East Asia and Australasia being affected, respectively.<sup>1</sup> In China, the prevalence was 0.12% in 1987 and 0.47% in 2012.<sup>2</sup> Apart from skin lesions, psoriasis is also now recognised as a systemic inflammatory disorder that relates to various comorbidities, such as metabolic syndrome, arthritis, malignancy and so on.<sup>3</sup> Poor appearances, together with comorbidities, significantly impair patients' daily functioning and cause significant psychological distress,<sup>4</sup> which can result in depression, suicidal ideation and substance abuse,<sup>5-8</sup> causing high social burdens, especially during the recurrent COVID-19 pandemics.<sup>9-11</sup>

Current clinical diagnosis and treatment for psoriasis must follow appropriate guidelines and consensus. Therefore, the choice of

To cite: Yang Z, Jin Y, Wang M, ABSTRACT treatment demands of patients during the COVID-19 pandemic: 2024;14:e079627. doi:10.1136/ available online. To view these online (https://doi.org/10.1136/ ZY and YJ contributed equally.

Received 06 September 2023 Accepted 17 January 2024

et al. Enhanced impact of

psoriasis severity on the

a cross-sectional study

bmjopen-2023-079627

Prepublication history

and additional supplemental

material for this paper are

files, please visit the journal

bmjopen-2023-079627).

based on a national psoriasis

registry in China. BMJ Open

#### Check for updates

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## **Correspondence to**

Dr Hang Li; drlihang@126.com and Professor Wen-Qing Li; wenqing\_li@bjmu.edu.cn



treatment for psoriasis primarily depends on the objective assessment of lesion severity of the disease, yet the demands of the patient are often neglected.<sup>12 13</sup> However, due to the chronic, non-fatal characteristics of psoriasis, individual perceptions of the disease can determine the impact of psoriasis on the quality of life of patients, which may then affect their treatment demands.<sup>14 15</sup> Thus, the treatment decisions should be driven by the real needs and expectations of each individual.

Furthermore, since healthcare access (eg, emerged telemedicine),<sup>16-19</sup> as well as the clinicians' treatment considerations to control psoriasis, have all changed during the recurrent COVID-19 pandemics,<sup>20</sup> patients' mental health condition, their perception of psoriasis and further treatment demands may altered accordingly.<sup>21-23</sup> From the treatment-decision aspect, the initiation of biologics for psoriasis decreased sharply during the COVID-19 pandemic, possibly due to the poor access to healthcare for patients and the lack of evidence on the relationship between COVID-19 infection and biological therapies for psoriasis at the beginning of the pandemic.<sup>24 25</sup> From a healthcare-seeking behaviour perspective, patients with psoriasis tended to cancel or defer their appointments, lose adherence to treatment and require prolonged prescription or treatment change during the COVID-19 pandemic.<sup>9 26–28</sup> All the above changes may be associated with deterioration of psoriasis and further symptoms of anxiety and depression,  $^{11}$   $^{22}$   $^{29}$   $^{30}$  although the association is complex and undetermined.  $^{10}$   $^{27}$  In contrast, from a quality-of-life perspective, the social-activity aspect assessed in a quality-of-life questionnaire became irrelevant during lockdown, which led to paradoxically improved quality of life among patients with psoriasis during the COVID-19 lockdown.<sup>1031</sup> Patients may perceive their psoriasis lesions as more acceptable because they are less worried about skin lesion appearances due to restricted social activities, and are more fearful of COVID-19 when receiving immunosuppressive treatment for psoriasis.<sup>23</sup> As a result, how patients' treatment demands changed during pandemics remains unknown. Thus, it is essential to reassess patients' treatment demands to improve personalised treatment during the pandemic. However, studies on changes in treatment demands from patients' perspectives during pandemics are limited.

This study aimed to examine the treatment demands of patients with psoriasis with varying disease severity and other clinical and personal characteristics in a real-world setting throughout the recurrent COVID-19 pandemic, hoping to provide references for personalised treatment strategies not only for patients with psoriasis during the COVID-19 pandemic but also for patients with all other chronic diseases in any future pandemic lockdowns.

#### **MATERIALS AND METHODS**

#### Study design, patients and data collected

This was a cross-sectional, multicentre study based on a nationwide real-world big data collection platform

BMJ Open: first published as 10.1136/bmjopen-2023-079627 on 17 February 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de I (ABES).

đ

ŧ

established by the Psoriasis Standardized Diagnosis and Treatment Center (also named Psoriasis Center) and led by the National Clinical Research Center for Skin and Immune Disease.<sup>32</sup> This data platform is the first and currently the largest psoriasis registry in China, and as of September 2021, had included data of 32014 patients with psoriasis from 228 hospitals across China. The registry collects data on demographics, medical history, clinical assessment, previous and current treatments for psoriasis, self-reported quality of life, and treatment demands at enrolment. The data preprocessing standards for derived otected variables and variables with potentially mistaken values are listed in online supplemental table S1.

All patients aged  $\geq 18$  years enrolled between August copyright, including for uses rela 2020 and September 2021 with complete baseline data were included. The differences in baseline characteristics between patients with complete and incomplete data are shown in online supplemental table S2.

#### Patient and public involvement

Patients were not involved in the design, conduct reporting or dissemination plans of our research.

#### **Study measures**

The study outcomes were patients' treatment demands, which were all collected through 'yes-or-no' questions in a face-to-face interview. The two primary treatment demands contained healing skin lesions quickly and improving mental health. The questionnaire also asked about other demands, including reducing social discrimination, working and socialising normally, relieving itchy feelings, relieving painful or burning feelings, and reducing the side effects of treatment and disease  $\mathbf{\bar{s}}$ relapses. All the aforementioned treatment demands were treated as binary variables. Quality of life was additionally assessed by the Dermatology Life Quality Index (DLOI).

The main exposure was psoriasis severity, which was assessed by the Psoriasis Area and Severity Index (PASI), body surface area (BSA) and the 5-point Investigator's Global Assessment (IGA).<sup>12 13</sup> According to the guidelines for the diagnosis and treatment of psoriasis in China (2023),<sup>33</sup> PASI score was categorised as mild (<3), moderate (3 to <10) and severe ( $\geq$ 10), whereas BSA (%) was categorised as mild (<3%), moderate (3% to technolog <10%) and severe ( $\geq 10\%$ ). The 5-point IGA categorised the severity level as clear/almost clear (0/1), mild (2), moderate (3) and severe (4).

Provincial COVID-19 data weres summarised from the official website of the National Health Commission of the People's Republic of China (http://www.nhc.gov.cn/ xcs/yqtb/list\_gzbd.shtml). Considering the maintenance period of both epidemic control measures and public response to the pandemic, the 7 days following the last day in which a new case was recorded were further classified into the same pandemic period. The COVID-19 pandemic variable was treated as binary according to the geographical location and enrolled day of each patient.

#### Statistical analysis

Descriptive statistics were performed for each variable stratified by each treatment demand using frequencies (percentages) for categorical variables and median (IQR) for continuous variables. Categorical variables were compared using  $\chi^2$  tests, whereas continuous variables were compared using the Kruskal-Wallis H test.

Multivariable logistic regression models were used to investigate the impact of psoriasis severity, as measured by PASI, BSA and IGA, separately, on each treatment demand stratified by whether the patient was enrolled during the COVID-19 pandemic. To reduce potential confounding factors, all models were adjusted for demographic characteristics (sex, age, body mass index (BMI), marriage status, education, employment and smoking habits) and clinical characteristics (psoriasis duration, family history, disease phenotype, nail/scalp/genital/palmoplantar involvement, comorbidities and previous treatment). PASI, BSA and IGA values were separately modelled in relation to each treatment demand and were treated as continuous and categorical variables separately. A Q-test attached to the fixed effect model was performed to detect the heterogeneity between the impact of psoriasis severity on treatment demands during the COVID-19 pandemic lockdowns and normal periods. Mediation analysis was employed to investigate the effect of PASI/BSA/IGA on treatment demands mediated by DLQI, adjusting for the same confounding set above and additionally for COVID-19 lockdowns. Other potential factors influencing the treatment demands were examined using the same multivariable logistic regression models investigating the impact of PASI on quick skin healing and mental health improvement demands while adding the COVID-19 pandemic as a covariate. All data analyses were conducted using STATA/SE (StataCorp LLC 2021, Stata Statistical Software: Release V.17), and a p<0.05 was considered statistically significant.

#### RESULTS

#### **General characteristics**

Among the 29412 adult patients enrolled as of September (online supplemental table S2), 22425 with 2021complete baseline information from 212 tertiary hospitals across China were enrolled in this study. Exactly 65.0% of patients were men (n=14567). The median age was 40 (IQR, 31-54) years, and the percentages of different age groups were as follows: 18-45 years, 60.3% (n=13515); 46–60 years, 26.9% (n=6033); ≥61 years, 12.8% (n=2877). The median PASI and DLQI scores were 7.2 and 8, respectively. Exactly 12.1% of the patients (n=2706) were enrolled during a COVID-19 lockdown in their provinces. Moreover, 89.7% (n=20111) and 38.0% (n=8531) of the patients demanded a speedy healing of the skin lesions and mental health improvement, respectively (table 1).

Patients demanding the rapid healing of skin lesions tended to be female, younger, employed, unmarried, have a college degree, have current smoking habits, enrolled during a normal period without the COVID-19 lockdown, have a shorter psoriasis duration, have a positive family history, have pustular or guttate psoriasis, have nail or scalp involvement and have a severer psoriasis condition, as measured by PASI, BSA and IGA, while not having palmoplantar involvement, comorbidities, such as psoriatic arthritis or a history of  $\neg$ use of biologics (all p<0.05). By comparison, patients demanding mental health improvement tended to be unemployed, have a longer psoriasis duration, have Š plaque, erythrodermic or arthropathic psoriasis, have lesions on special areas including nails, scalps, hands/ soles, and genitals, have more severe psoriasis conditions, and have deteriorated quality of life, while not having a college degree, smoking habits, pustular or guttate psoriasis or comorbidities (all p < 0.05). Patients' characteristics stratified by other treatment demands are shown in online supplemental table S3. ing

## Impact of psoriasis severity on treatment demands stratified by the COVID-19 pandemic

for uses related Both multivariable logistic regression and trend tests confirmed that the increasing psoriasis severity, as measured by PASI, significantly stimulated patients' primary treatment demands of healing skin lesions 5 rapidly (OR, 1.45; 95% CI 1.27 to 1.65; p<0.001 for e severe PASI vs mild PASI; and OR 1.02; 95% CI 1.01 to 1.02; p<0.001 in the trend test) and improving mental health (OR 2.21; 95% CI 2.03 to 2.40; p<0.001 for severe PASI vs mild PASI; and OR 1.03; 95% CI 1.02 to 1.03; p<0.001 in the trend test) during a  $\Xi$ normal period without COVID-19 lockdown (shown in figure 1A,B; and online supplemental table S4). ≥ The disease severity-triggered primary treatment demands further increased during the COVID-19 lockdowns, including healing skin lesions rapidly (OR 2.19; 95% CI 1.57 to 3.05 for severe PASI vs mild PASI; p<0.001) and improving mental health (OR 2.82; 95% CI 2.24 to 3.55 for severe PASI vs mild PASI, p<0.001), despite the statistical insignificance (both p=0.064 in the heterogeneity Q-test). Other treatment demands, including reducing social discrimination, working and socialising normally, relieving painful or burning feelings, relieving itchy feelings and reducing **o** the treatment side effects, were also significantly stimulated by deteriorated skin conditions measured by 3 PASI (all p<0.05); moreover, the degree of this stimulation further intensified during the COVID-19 lockdown (shown in figure 1C-G). The exception was the demand for reducing relapses, which significantly declined as PASI increased. Nevertheless, the magnitude of this decline decreased during the pandemic lockdown (OR 0.61; 95% CI 0.49 to 0.75, p<0.001 for severe PASI vs mild PASI during a non-COVID-19 period and OR 0.81; 95% CI 0.58 to 1.12; p=0.196

Table 1         Demographic and clinical ch	naracteristics stratifie	d by primary treatme	ent demands				
	Healing skin lesior	ns rapidly		Improving mental	health		
	Yes (n=20 111)	No (n=2314)	P value	Yes (n=8531)	No (n=13894)	P value	Total (n=22425)
Male, n (%)	13 005 (64.7)	1562 (67.5)	0.007	5491 (64.4)	9076 (65.3)	0.144	14567 (65.0)
Age, y, median (IQR)	40 (31–53)	42 (33–55)	<0.001	40 (31–53)	40 (31–54)	0.227	40 (31–54)
BMI, kg/m <sup>2</sup> , median (IQR)	24.0 (21.7–26.7)	24.2 (21.9–26.9)	0.099	24.0 (21.8–26.7)	24.1 (21.7–26.8)	0.405	24.0 (21.7–26.7)
Unemployment*, n (%)	1755 (11.2)	239 (13.3)	0.001	833 (12.3)	1161 (10.8)	0.003	1994 (11.4)
Married, n (%)	15316 (76.2)	1888 (81.6)	<0.001	6544 (76.7)	10 660 (76.7)	0.979	17204 (76.7)
Bachelor's degree, n (%)	7064 (35.1)	764 (33.0)	0.044	2860 (33.5)	4968 (35.8)	0.001	7828 (34.9)
Current smoker, n (%)	5443 (27.1)	580 (25.1)	0.040	2119 (24.8)	3904 (28.1)	<0.001	6023 (26.9)
COVID-19 lockdown, n (%)	2394 (11.9)	312 (13.5)	0.027	1032 (12.1)	1674 (12.1)	0.913	2706 (12.1)
Psoriasis duration, year, median (IQR)	6 (2–14)	8 (2–15)	<0.001	8 (2–15)	6 (1–14)	<0.001	6 (2–14)
Family history, n (%)	3459 (17.2)	357 (15.4)	0.032	1452 (17.0)	2364 (17.0)	0.991	3816 (17.0)
Psoriasis phenotype†, n (%)							
Plaque psoriasis	16 335 (81.2)	1896 (81.9)	0.406	7105 (83.3)	11 126 (80.1)	<0.001	18231 (81.3)
Erythrodermic psoriasis	219 (1.1)	23 (1.0)	0.675	121 (1.4)	121 (0.9)	<0.001	242 (1.1)
Pustular psoriasis	609 (3.0)	49 (2.1)	0.014	216 (2.5)	442 (3.2)	0.005	658 (2.9)
Guttate psoriasis	2739 (13.6)	277 (12.0)	0.028	978 (11.5)	2038 (14.7)	<0.001	3016 (13.4)
Arthropathic psoriasis	1293 (6.4)	297 (12.8)	<0.001	668 (7.8)	922 (6.6)	0.001	1590 (7.1)
Lesions on special areas, n (%)							
Nail	4861 (24.2)	504 (21.8)	0.011	2130 (25.0)	3235 (23.3)	0.004	5365 (23.9)
Scalp	13 127 (65.3)	1451 (62.7)	0.014	5709 (66.9)	8869 (63.8)	<0.001	14578 (65.0)
Palmoplantar	3928 (19.5)	530 (22.9)	<0.001	1863 (21.8)	2595 (18.7)	<0.001	4458 (19.9)
Genital	2681 (13.3)	333 (14.4)	0.157	1281 (15.0)	1733 (12.5)	<0.001	3014 (13.4)
Disease severity, median (IQR)							
PASI	7.2 (3.0–15.0)	5.9 (2.6–12.0)	<0.001	9.1 (3.9–17.4)	6.0 (2.7–12.8)	<0.001	7.2 (3.0–14.6)
BSA, %	10.0 (3.0–30.0)	9.2 (3.0–22.4)	<0.001	14.0 (5.0–30.0)	8.0 (3.0–25.0)	<0.001	10.0 (3.0–30.0)
IGA	3 (2–3)	2 (2–3)	<0.001	3 (2–3)	3 (2–3)	<0.001	3 (2–3)
DLQI, median (IQR)	8 (3–12)	8 (2–12)	0.072	10 (6–15)	6 (2–10)	<0.001	8 (3–12)
Comorbidity‡, n (%)	2850 (14.2)	395 (17.1)	<0.001	1177 (13.8)	2068 (14.9)	0.010	3245 (14.5)
Previous use of biologics§	1726 (8.6)	256 (11.1)	<0.001	732 (8.6)	1250 (9.0)	0.286	1982 (8.8)
*The unemployment rate was calculated †Phenotypes were not mutually exclusive ‡Comorbidity presented the existence of tumours, endocrine diseases and so on. §Biologics included tumour necrosis fact. BMI. body mass index: BSA, body surfac	in the working-age pol a, thus the total percen any disease condition or-α inhibitors and inte ce area: DLOI. Dermatc	oulation, which exclud tage was higher than <sup>-</sup> is, including cardiovase rfeukin inhibitors. bloov Life Quality Index	ed retired patien 100%. cular diseases, rr c. IGA. Investiaat	ts and students. sspiratory diseases, kid or's Global Assessmen	ney diseases, rheumati :: PASI. Psoriasis Area a	c diseases, dige and Severity Inc	sstive diseases, ex.



Figure 1 OR for the association between each treatment demand and psoriasis severity by different measures (PASI/BSA/ IGA) during COVID-19 lockdowns (red line) and non-lockdown periods (blue line). (A) Treatment demand for healing skin lesions rapidly. (B) Treatment demand for improving mental health. (C) Treatment demand for reducing social discrimination. (D) Treatment demand for working and socialising normally. (E) Treatment demand for relieving painful or burning feelings. (F) Treatment demand for relieving itchy feelings. (G) Treatment demand for reducing the side effects of treatment. (H) Treatment demand for reducing relapses. BSA, body surface area; IGA, Investigator's Global Assessment; PASI, Psoriasis Area and Severity Index.

during a COVID-19 lockdown; heterogeneity O-test, p=0.001; shown in figure 1H).

## Impact of psoriasis severity by different instruments on treatment demands stratified by the COVID-19 pandemic

Similar patterns of change in each treatment demand were also found as BSA and IGA increased during the normal period. However, the two measures motivated the treatment demands slightly differently during the pandemic lockdowns. Specifically, the magnitude of increasing BSAtriggered demands of rapidly healing skin lesions hardly changed during the pandemic lockdowns (OR 1.33; 95% CI 1.17 to 1.50; p<0.001 for severe BSA vs mild BSA during a normal period and OR 1.38; 95% CI 0.999 to 1.896; p=0.051 during the pandemic lockdown; heterogeneity Q-test, p=0.663), whereas that of IGA-triggered demands significantly increased (OR 1.64; 95% CI 1.35 to 1.99; p<0.001 for IGA=4 vs IGA=0/1 during the normal period and OR 2.70; 95% CI 1.63 to 4.49; p<0.001 during the pandemic lockdown; heterogeneity O-test, p=0.005). In contrast, the magnitude of the increase in demands of improving mental health triggered by BSA significantly increased during the pandemic (OR 2.01; 95% CI 1.85 to 2.19; p<0.001 and OR 3.27; 95% CI 2.57 to 4.15; p<0.001; heterogeneity Q-test, p<0.001), whereas that triggered by IGA hardly changed (OR 2.21; 95% CI 1.94 to 2.51; p<0.001 and OR 1.91; 95% CI 1.36 to 2.68; p<0.001; heterogeneity Q-test, p=0.971; shown in figure 1A,B and online supplemental tables S5 and S6).

## Impact of psoriasis severity on treatment demands mediated by quality of life

Further mediation analysis showed that increasing PASI motivated patients' treatment demands mainly by ല ă

data mining, AI training, and similar technologies

deteriorating their quality of life, including improving mental health (47.1%), reducing social discrimination (mediated proportion, 49.0%), working and socialising normally (72.1%), relieving painful (40.8%) or itchy (73.2%) feelings and reducing the treatment side effects (74.3%). However, the proportion of the DLQI-mediated effect was small in the total effect of PASI on the demands for reducing relapses (7.6%) and guickly healing skin lesions (0.6%). The aforementioned results were replicated when disease severity was examined by BSA and IGA (table 2).

## Potential factors influencing treatment demands

Protected by copyr Apart from disease severity, multivariable logistic regression analysis also identified female sex (OR 1.23; 95% CI 1.11 to 1.36; p<0.001), smoking status (OR 1.17; 95% CI 1.04 to 1.30; p=0.005), pustular psoriasis (OR 1.71; 95% CI 1.26 to 2.32; p=0.001) and nail involvement (OR 1.28; 95% CI 1.14 to 1.44, p<0.001) to be significantly <u></u> correlated with a higher demand for quick skin lesion healing. However, older age (OR 0.994; 95% CI 0.991 to ₫ 0.998; p=0.004), married status (OR 0.82; 95% CI 0.72 to r uses 0.94; p=0.003), unemployed status (OR 0.82; 95% CI 0.70 to 0.95; p=0.010), COVID-19 lockdown (OR 0.87; 95% CI 0.77 to 0.99; p=0.037), arthropathic psoriasis (OR 0.55; Гe 95% CI 0.47 to 0.64; p<0.001), palmoplantar involvement ated (OR 0.75; 95% CI 0.67 to 0.85; p<0.001) and comorbidities (OR 0.86; 95% CI 0.76 to 0.97; p=0.018) were found to **b**e significantly correlated with lower demand (table 3). be significantly correlated with lower demand (table 3).

Moreover, the demand for the improvement of mental health was significantly higher in patients with arthropathic psoriasis (OR 1.22; 95% CI 1.09 to 1.37; p=0.001) and palmoplantar involvement (OR 1.09; 95% CI 1.01 to

Table 2 Proportion of cau	usal effect	of disease	e severity on ti	reatment c	lemands,	as mediated l	by quality	of life	
	PASI			BSA			IGA		
Treatment demands	Indirect effect*	Total effect†	Mediated proportion‡	Indirect effect*	Total effect†	Mediated proportion‡	Indirect effect*	Total effect†	Mediated proportion‡
Healing skin lesions rapidly	< 0.001	0.001	0.6%	< 0.001	0.001	1.4%	< 0.001	0.019	0.3%
Improving mental health	0.009	0.020	47.1%	0.004	0.007	56.7%	0.098	0.186	52.6%
Reducing social discrimination	0.006	0.013	49.0%	0.003	0.005	53.5%	0.064	0.118	54.3%
Working and socialising normally	0.025	0.035	72.1%	0.010	0.015	67.7%	0.260	0.289	90.0%
Relieving painful or burning feelings	0.010	0.024	40.8%	0.004	0.009	45.5%	0.102	0.212	48.2%
Relieving itchy feelings	0.011	0.015	73.2%	0.004	0.003	139.4%	0.106	0.244	43.3%
Reducing the side effects of treatment	0.016	0.021	74.3%	0.006	0.007	83.4%	0.162	0.145	111.9%
Reducing relapses	< 0.001	0.003	7.6%	< 0.001	0.001	5.9%	0.004	0.079	5.4%

\*The indirect effect refers to the effect of PASI/BSA/IGA on each treatment demand mediated by quality of life.

The total effect refers to the sum of direct effects of PASI/BSA/IGA on each treatment demand and the indirect effects mediated by quality of life.

‡The mediated proportion equals to the indirect effect divided by the total effect.

BSA, body surface area; IGA, Investigator's Global Assessment; PASI, Psoriasis Area and Severity Index.

Table 3         Relationship between other	er patient characteristics and pr	imary treatment	demands	
	Healing skin lesions rapidly		Improving mental health	
Patient characteristics	OR (95% CI)	P value	OR (95% CI)	P value
Sex (reference: male)	1.23 (1.11 to 1.36)	<0.001	1.04 (0.98 to 1.11)	0.205
Age	0.994 (0.991 to 0.998)	0.004	0.993 (0.991 to 0.996)	<0.001
Body mass index	0.997 (0.990 to 1.003)	0.281	0.9955 (0.9914 to 0.9996)	0.030
Marriage (reference: unmarried)	0.82 (0.72 to 0.94)	0.003	1.06 (0.98 to 1.14)	0.166
Bachelor's degree	1.01 (0.92 to 1.12)	0.912	0.90 (0.84 to 0.95)	0.001
Unemployment	0.82 (0.70 to 0.95)	0.010	1.08 (0.98 to 1.20)	0.112
Current smoker	1.17 (1.04 to 1.30)	0.005	0.81 (0.75 to 0.86)	< 0.001
COVID-19 lockdowns	0.87 (0.77 to 0.99)	0.037	1.02 (0.93 to 1.11)	0.726
Disease course	0.9996 (0.9989 to 1.0004)	0.319	0.9999 (0.9993 to 1.0005)	0.744
Family history	0.93 (0.82 to 1.05)	0.225	1.03 (0.95 to 1.11)	0.457
Psoriasis phenotype (reference: plaque	e psoriasis)			
Erythrodermic psoriasis	1.19 (0.76 to 1.86)	0.435	1.09 (0.84 to 1.42)	0.503
Pustular psoriasis	1.71 (1.26 to 2.32)	0.001	0.77 (0.65 to 0.92)	0.003
Guttate psoriasis	1.14 (0.9995 to 1.31)	0.051	0.78 (0.71 to 0.84)	<0.001
Arthropathic psoriasis	0.55 (0.47 to 0.64)	<0.001	1.22 (1.09 to 1.37)	0.001
Lesions on specific areas				
Nail	1.28 (1.14 to 1.44)	<0.001	0.97 (0.90 to 1.04)	0.373
Scalp	1.07 (0.97 to 1.18)	0.158	1.0005 (0.94 to 1.06)	0.987
Palmoplantar	0.75 (0.67 to 0.85)	<0.001	1.09 (1.01 to 1.18)	0.027
Genital	0.93 (0.81 to 1.07)	0.323	1.08 (0.99 to 1.17)	0.087
Comorbidity	0.86 (0.76 to 0.97)	0.018	0.90 (0.83 to 0.97)	0.012
Previous use of biologics	0.87 (0.75 to 1.01)	0.077	1.02 (0.92 to 1.13)	0.682

The relationship between other patient characteristics and primary treatment demands was identified by the same logistic regression models examining the impact of PASI on treatment demands.

PASI, Psoriasis Area and Severity Index.

1.18, p=0.027). However, this was lower among patients with older age (OR 0.993; 95% CI 0.991 to 0.996, p<0.001), higher BMI (OR 0.9955; 95% CI 0.9914 to 0.9996; p=0.030), a college education (OR 0.90; 95% CI 0.84 to 0.95; p=0.001), smoking status (OR 0.81; 95% CI 0.75 to 0.86; p<0.001), pustular psoriasis (OR 0.77; 95% CI 0.65 to 0.92; p=0.003), guttate psoriasis (OR 0.78; 95% CI 0.71 to 0.84; p<0.001) and comorbidities (OR 0.90; 95% CI 0.83 to 0.97; p=0.012).

## DISCUSSION

In this cross-sectional study, it was observed that patient demands for healing skin lesions and improving mental health significantly increased as psoriasis worsened, especially during the COVID-19 pandemic. Different psoriasis severity measures have different emphases in reflecting patients' treatment demands, which were magnified during the pandemic. The impact of disease severity on most treatment demands was mediated by deteriorated quality of life, except for the demands of rapid skin healing and relapse reduction, and thus other factors that stratified major treatment demands were also examined.

Protected by copyright, including for uses related to text and data mining, Al trair Patient-centred intervention is crucial for the treatment of psoriasis due to the chronic and non-fatal characteristics of the condition, in addition to the considerable disparity in prices of various treatment choices, especially in recent years with recurrent pandemic lockdowns. During a normal period, all treatment demands, ranging from improving the appearance of skin lesions and relieving irritating symptoms to psychological and daily functional support, significantly increased as psoriasis deteriorated, suggesting the need for more intensive treatment and psychological counselling for patients. The only exception was the demand for reducing relapses, which was demanded in only 4.7% of patients and further decreased as disease severity increased, indicating that most Chinese patients have recognised the chronic nature of psoriasis and accepted the recurrent relapses and living with a small number of skin lesions, thereby suggesting that clinicians should be aware that patients may have poor compliance in their remission periods.

Compared with normal periods, all treatment demands, including those for rapidly healing skin lesions and improving mental health, were further triggered by disease

severity during pandemic lockdowns (shown in figure 1). This differed from previous reports, which demonstrated that patients' quality of life, as measured by DLOI, was less influenced by psoriasis during pandemic lockdowns.<sup>10 31</sup> The reason for the difference in results is complex. On one hand, because social activities were restricted, patients worried less about skin lesion appearance when socialising and were more fearful about contracting infectious diseases rather than non-fatal psoriasis. Thus, better quality of life, as indicated by DLQI, was observed.<sup>10 31</sup> Our multivariable logistic models also showed that the COVID-19 pandemic itself was a protective factor in reducing the demands of healing skin lesions (table 3). On the other hand, the restrictions in travelling and difficulties in accessing medical resources may exacerbate psoriasis and enhance treatment demands.<sup>22</sup> Although the pandemic lockdowns reduced the impact of psoriasis on socialising, the pandemic and self-isolations themselves could exert psychological impact on patients with psoriasis, such as health anxiety and low mood,<sup>10 21</sup> creating a vicious circle of worsening mental health and deteriorated psoriasis. Taking all these factors together, the study showed enhanced treatment demands in patients with more severe psoriasis during the pandemic lockdowns, suggesting that patients' treatment demands were more influenced by psoriasis and stress conditions rather than the reduced need for socialising. These indicate for clinicians that a more intensive treatment strategy with lasting effects and enhanced mental support is needed during lockdown. In addition, increasing evidence in recent years has shown that immunosuppressive treatment for psoriasis, including biologics, does not increase the risk of COVID-19 infection or the related complications, reinforcing the necessity of more intensive therapy during the pandemic.<sup>28 34 35</sup> Besides, a more accessible pathway, such as telemedicine and online medicine service, should be promoted as an 'add-on' for in-person clinics,<sup>22 30</sup> to facilitate access to healthcare during pandemic lockdowns. All these factors might be generalised and integrated into the management of other chronic non-fatal diseases,<sup>21</sup> such as atopic diseases, during future pandemics to meet patients' treatment needs.

To further help recognise patients' needs according to their clinical manifestations in daily clinics, this study compared the impact of disease severity by different measures on each treatment demand. PASI, BSA and IGA are all instruments measuring psoriasis severity and were found to be significantly correlated with one another.<sup>36</sup> PASI takes both the area coverage and lesion appearance into account, yet it is time-consuming to calculate. In contrast, BSA and IGA are easier to understand, yet only represent the lesion coverage or lesion appearance.<sup>12</sup> In this study, an overall more irritating skin appearance presented by a higher IGA further stimulated the demands for the quick relief of skin lesions themselves during the pandemic lockdown, whereas the larger lesion coverage presented by higher BSA further motivated demands for psychological solutions, including improving mental

BMJ Open: first published as 10.1136/bmjopen-2023-079627 on 17 February 2024. Downloaded Enseignement Superieur ( Protected by copyright, including for uses related to text and dat from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de l (ABES).

health and reducing social discrimination. Since PASI is difficult to obtain, this study suggests that BSA should be used as a 'first-line' surrogate to represent the enhanced psychological needs of patients, whereas IGA should be used to represent the increased need for more intensive therapy during pandemic lockdowns.

As most previous studies focused on the quality of life of patients with psoriasis, which revealed that worsened quality of life was associated with worsened psoriasis,<sup>37  $\frac{3}{8}$ </sup> this study further investigated the impact of  $\neg$ psoriasis on treatment demands mediated by quality of **2** life. In this study, quality of life was measured by DLQI, which reflected patients' lesion feelings, daily activities, leisure, work and study, personal relationships and treatment burden. We confirmed that increasing disease severity deteriorated patients' quality of life based on the aforementioned aspects, which further motivated corresponding treatment demands. However, although prevalent in the psoriasis population, <2% of the demand for quick skin lesion healing was mediated by deteriorated quality of life, indicating the existence of other factors influencing treatment demands.

Thus, this study further examined other factors potentially stratifying treatment demands. Young and female patients were found to have worse quality of life in previous studies,<sup>37 39 40</sup> as well as higher treatment demands for rapid skin lesion healing in this study. Unmarried and employed patients without comorbidities were also found to have stronger demands for quick healing. These might be because female, young, unmarried and employed patients have higher requirements for self-image, and patients without comorbidities have fewer concerns regarding polypharmacy and drug interactions due to underlying diseases. Additionally, the same demands for quick healing were higher in patients with pustular psoriasis, which presents with fever, painful skin and frequent flare-ups,<sup>41</sup> and in patients with nail psori-≥ asis, which undermines daily function.<sup>42</sup> Thus, a more intensive treatment strategy is needed for these patients. ğ Additionally, more psychological care should be provided to younger patients without a college education, as they may lack a basic understanding of the disease and were S found to have higher demands for mental support in this study. The same support was also needed in patients with arthropathic psoriasis and palmoplantar psoriasis, which were linked with internalised stigma and poorer quality of life.43 44

Although, to our knowledge, this study is the largest realworld study to date investigating the treatment demands of patients with psoriasis during the pandemic lockdowns, there were limitations. First, the Psoriasis Center programme enrolled patients from specific dermatological clinics, and a certain proportion of patients declined the enrollment request. Thus, the study population may not represent the general psoriasis population. Second, the demand for improving mental health was collected as a binary variable, while the psychological or psychiatric condition was not systematically assessed using specialised

BMJ Open: first published as 10.1136/bmjopen-2023-079627 on 17 February 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

scales, such as Generalised Anxiety Disorder-2, Patient Health Questionnaire-2 and Short Form-12 Health Survey.<sup>11 22 45</sup> Further studies are warranted to quantitatively investigate patients' mental health condition and the degree of each treatment demand using specialised scales. Third, there was an issue regarding the missing data for this data platform. However, as the missing rate was not high, and missing at random was considered (online supplemental table S2), a complete-case analysis was considered sufficient for handling missing data and, therefore, used. Fourth, since the information on residence place was not collected, the COVID-19 pandemic information was matched to each patient only at a province level, even though the pandemic was prevented with a precise approach in China.

## CONCLUSION

An increase in psoriasis severity significantly stimulates patients' treatment demands from guickly healing skin lesions and improving mental health aspects, especially during the pandemic lockdowns, indicating the need for an accessible pathway for patients with psoriasis getting more intensive treatment and mental support during future pandemics. To better recognise and meet patients' treatment demands during the pandemic, we suggest that BSA is used to determine the psychological needs of patients, while IGA should be used to reflect the desire to quickly heal lesions. Other demographic and clinical characteristics of each patient should also be considered for a more personalised treatment strategy during future pandemics. Moreover, since the COVID-19 pandemic is nearing its end in many countries, the results of this study could provide hints for personalised treatment for patients with non-fatal chronic diseases in future pandemic lockdowns.

#### **Author affiliations**

<sup>1</sup>Department of Dermatology and Venerology, National Clinical Research Center for Skin and Immune Diseases, Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, and NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Peking University First Hospital, Beijing, China

<sup>2</sup>State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, and Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China

<sup>3</sup>Peking University - Yunnan Baiyao International Medical Research Center, Peking University, Beijing, China

Acknowledgements The authors would like to acknowledge the contributions made by all collaborating units of the Psoriasis Center with data collection. The authors would also like to thank all patients who participated in this study.

**Contributors** All authors were involved in the study design. ZY cleaned the clinical data, conducted the statistical analysis, created the initial manuscript and revised the manuscript according to the suggestions of other authors. YJ provided statistical support and helped revise the manuscript. MW and RL helped provide clinical guidance and revise the manuscript. W-QL provided statistical guidance and revised the manuscript. HL revised the manuscript, supervised the overall research project, accepts full responsibility for the work of the study as guarantor, had access to the data, and controlled the decision to publish. All authors read and approved the final manuscript.

**Funding** This work was supported by the National Key Research and Development Program of China (2023YFC2508100), PKU-Baidu Fund (grant number: 2020BD012).

**Disclaimer** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and this study protocol was reviewed and approved by ethics committee of the Peking University First Hospital (approval number: 2020-scientific research-255) and the Human Genetic Resources Management Office of the Ministry of Science and Technology of China (approval number: 2022-CJ0021). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. This study was conducted using deidentified data from the real-world data collection platform of the Psoriasis Standardized Diagnosis and Treatment Center (http://www.psocenter.cn/). Data are publicly available on request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### ORCID iDs

Zhihui Yang http://orcid.org/0000-0003-1193-6894 Yu Jin http://orcid.org/0000-0002-1143-6702 Wen-Qing Li http://orcid.org/0000-0002-8336-5552

#### REFERENCES

- Parisi R, Iskandar IYK, Kontopantelis E, *et al.* National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. *BMJ* 2020;369:m1590.
- 2 Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol 2012;22:663–7.
- 3 Takeshita J, Grewal S, Langan SM, *et al*. Psoriasis and comorbid diseases: epidemiology. *J Am Acad Dermatol* 2017;76:377–90.
- 4 Armstrong AW, Schupp C, Wu J, *et al.* Quality of life and work productivity impairment among psoriasis patients: findings from the national psoriasis foundation survey data 2003-2011. *PLoS One* 2012;7:e52935.
- 5 Bang CH, Yoon JW, Chun JH, *et al.* Association of psoriasis with mental health disorders in South Korea. *JAMA Dermatol* 2019;155:747–9.
- 6 Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015;135:984–91.
- 7 Liu L, Lin N-X, Yu Y-T, *et al.* Epidemiology of mental health comorbidity in patients with psoriasis: an analysis of trends from 1986 to 2019. *Psychiatry Res* 2023;321:115078.
- 8 Schielein MC, Tizek L, Knobloch L, et al. Psoriasis and addiction: assessing mental health based on a cross-sectional study in Germany. Eur J Dermatol 2021;31:722–9.

## Open access

- 9 Chiu H-Y, Chang Liao N-F, Lin Y, et al. Perception of the threat. mental health burden, and healthcare-seeking behavior change among psoriasis patients during the COVID-19 pandemic. PLoS ONE 2021;16:e0259852.
- Lada G, Chinoy H, Talbot PS, et al. Impact of the COVID-19 10 pandemic on the mental health and quality of life of patients with psoriasis in tertiary care; a one-year follow-up. Acta Derm Venereol 2022;102:2464.
- 11 Mahil SK, Yates M, Yiu ZZN, et al. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol 2021:35:e636-40
- 12 Armstrong AW, Siegel MP, Bagel J, et al. From the medical board of the National psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol 2017;76:290-8.
- 13 Langley RGB, Feldman SR, Nyirady J, et al. The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 2015;26:23-31.
- Abrouk M, Nakamura M, Zhu TH, et al. The impact of PASI 75 and 14 PASI 90 on quality of life in moderate to severe psoriasis patients. J Dermatolog Treat 2017;28:488-91.
- Blome C, Gosau R, Radtke MA, et al. Patient-relevant treatment 15 goals in psoriasis. Arch Dermatol Res 2016:308:69-78.
- 16 Hoffman DA. Increasing access to care: telehealth during COVID-19. J Law Biosci 2020;7:Isaa043.
- 17 Mistry SK, Ali ARMM, Yadav UN, et al. Older adults with noncommunicable chronic conditions and their health care access amid COVID-19 pandemic in Bangladesh: Findings from a cross-sectional study. PLoS One 2021;16:e0255534.
- 18 Nouri S, Khoong EC, Lyles CR, et al. Addressing equity in telemedicine for chronic disease management during the Covid-19 pandemic. NEJM Catal Innov Care Deliv 2020:1.
- Sinch K, Kondal D, Mohan S, et al. Health, psychosocial, and 19 economic impacts of the COVID-19 pandemic on people with chronic conditions in India: a mixed methods study. BMC Public Health 2021;21:685.
- 20 Elmas ÖF, Demirbas A, Kutlu Ö, et al. Psoriasis and COVID-19: a narrative review with treatment considerations. Dermatol Ther 2020:33:e13858
- Lada G, Talbot PS, Bewley A, et al. Mental health and dermatology 21 practice in the COVID-19 pandemic. Clin Exp Dermatol 2020:45:816-7.
- Kuang Y, Shen M, Wang Q, et al. Association of outdoor activity 22 restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: a web-based survey. J Am Acad Dermatol 2020;83:670-2.
- Rodríguez-Villa Lario A, Vega-Díez D, González-Cañete M, et al. 23 Patient's perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice. J Dermatolog Treat 2022;33:1185-7.
- Penso L, Dray-Spira R, Weill A, et al. Drop in biological initiation 24 for patients with psoriasis during the COVID-19 pandemic. Br J Dermatol 2021;185:671-3.
- Pirro F, Caldarola G, Chiricozzi A, et al. The impact of COVID-19 25 pandemic in a cohort of Italian psoriatic patients treated with biological therapies. J Dermatolog Treat 2022;33:1079-83.
- 26 Ninosu N, Roehrich F, Diehl K, et al. Psoriasis care during the time of COVID-19: real-world data on changes in treatments and appointments from a German university hospital. Eur J Dermatol 2021;31:183-91.

- Quirke-McFarlane S. Weinman J. Cook ES. et al. Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. Br J Dermatol 2023;188:610-7.
- 28 Polat Ekinci A, Pehlivan G, Gökalp MO. Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: a single-center experience. Dermatol Ther 2021;34:e14700.
- Wang Q, Luo Y, Lv C, et al. Nonadherence to treatment and patient-29 reported outcomes of psoriasis during the COVID-19 epidemic: a web-based survey. Patient Prefer Adherence 2020;14:1403-9.
- van de Kerkhof PCM. Future perspectives on care for patients with 30 psoriasis. What did we learn during the COVID-19. J Dermatolog . Treat 2021;32:477–77.
- 31 Boch K, Zillikens D, Ludwig RJ, et al. Paradoxical improvement of life quality in the COVID-19 era in psoriasis patients. PLoS One 2022:17:e0275293
- 32 Yang Z, Yao X, Wang M, et al. Updates in psoriasis diagnosis and treatment status in China: results from the National psoriasis center registry. Chin Med J (Engl) 2023;136:2874-6.
- Committee on Psoriasis, Chinese Society of Dermatology. Guideline 33 for the diagnosis and treatment of psoriasis in China (2023 edition). Chin J Dermatol 2023;56:573-625.
- Penso L, Dray-Spira R, Weill A, et al. Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France. Br J Dermatol 2022;186:59-68.
- 35 Kartal SP, Celik G, Yılmaz O, et al. The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkey. J Dermatolog Treat 2022;33:2137-44.
- 36 Lane S, Lozano-Ortega G, Wilson J, et al. Assessing severity in psoriasis: correlation of different measures (PASI, BSA, And IGA) in a Canadian real-world setting. Value in Health 2016;19:A122.
- Daudén E, Pujol RM, Sánchez-Carazo JL, et al. Demographic 37 characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: the VACAP study. Actas Dermosifiliogr 2013;104:807-14.
- 38 Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the corrona psoriasis registry. BMJ Open 2019;9:e027535.
- Sampogna F. Linder D. Piaserico S. et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol 2014;94:411-414:411-4 .:.
- 40 Maul J-T, Navarini AA, Sommer R, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. J Eur Acad Dermatol Venereol 2019;33:700-8.
- Choon SE, Lai NM, Mohammad NA, et al. Clinical profile, morbidity, 41 and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2014;53:676-84.
- Thomas L, Azad J, Takwale A. Management of nail psoriasis. Clin 42 Exp Dermatol 2021:46:3-8.
- 43 Alpsoy E, Polat M, FettahlioGlu-Karaman B, et al. Internalized stigma in psoriasis: a multicenter study. J Dermatol 2017;44:885-91.
- Sampogna F, Tabolli S, Söderfeldt B, et al. Measuring guality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006:154:844-9.
- Grozdev I, Kast D, Cao L, et al. Physical and mental impact of 45 psoriasis severity as measured by the compact Short Form-12 health survey (SF-12) quality of life tool. J Invest Dermatol 2012;132:1111-6.

, and

similar

Article type: Original Article

**Title:** Enhanced impact of psoriasis severity on treatment demands of patients during the COVID–19 pandemic: A cross–sectional study based on a national psoriasis registry in China

**Authors:** Z. Yang, MD<sup>1†</sup>; Y. Jin, PhD<sup>2†</sup>; M. Wang, MD<sup>1</sup>; R. Li, MD<sup>1</sup>; W. Li, PhD<sup>2\*</sup>; H. Li, MD<sup>1,3\*</sup>

<sup>1</sup>Department of Dermatology and Venerology, Peking University First Hospital, Beijing 100034, China; Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, Peking University First Hospital, Beijing 100034, China; National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China; and NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Peking University First Hospital, Beijing 100034, China.

2State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing 100142, China

<sup>3</sup>Peking University – Yunnan Baiyao International Medical Research Center

<sup>†</sup>These authors contributed equally.

## Corresponding author (W. Li and H. Li contributed equally):

Wenqing Li, PhD, Prof.

No.52 Fucheng Road, Haidian District

Beijing, P. R. China. 100143

Tel: (86)18010276738

Email: wenging li@bjmu.edu.cn

Hang Li, MD., Prof.

No.1 Xi'anmen Street, Xicheng District

Beijing, P. R. China. 100034

Tel: (86)-10-83573075

Email: drlihang@126.com

ORCID: 0000-0002-7343-3865

## **Supplemental Material**

Table S1. Data preprocessing standards for derived variables and variables with
potential mistaken values3
Table S2. Comparison of baseline characteristics between full population and study
population with complete data4
Table S3. Baseline characteristics stratified by treatment demands
Table S4. Mutlivariable logistic regression models examining the impact of PASI on
treatment demands stratified by COVID-19 lockdowns10
Table S5. Mutlivariable logistic regression models examining the impact of BSA on
treatment demands stratified by COVID-19 lockdowns11
Table S6. Mutlivariable logistic regression models examining the impact of IGA on
treatment demands stratified by COVID-19 lockdowns12

F	-
Patient characteristics	Data preprocessing standards
Height	Was treated as a missing value if height<80cm or >200cm
Weight	Was treated as a missing value if weight <25kg or >200kg
Psoriasis duration	The year of enrollment minus the year of diagnosis
Family history	Was treated as a missing value if the patient was unsure about the family history
Psoriatic arthritis	Was treated as "yes" if the patient was diagnosed with arthropathic psoriasis or psoriatic arthritis
Body Surface Area	Was treated as a missing value if BSA<75% for patients diagnosed with

erythrodermic psoriasis

**Table S1.** Data preprocessing standards for derived variables and variables with potential mistaken values

**Patient characteristics** 

	(n=29 412) <sup>a</sup>	population (n=22	number and
		425)	proportion
Male, No. (%)	19 120 (65.1)	14 567 (65.0)	53 (0.2)
Age, median (IQR), y	41 (32–54)	40 (31–54)	241 (0.8)
BMI, median (IQR), kg/m <sup>2</sup>	24.0 (21.6–26.6)	24.0 (21.7–26.7)	678 (2.3)
Unemployment <sup>b</sup> , No. (%)	2544 (11.5)	1994 (11.4)	1019 (3.5)
Married, No. (%)	22 004 (77.5)	17 204 (76.7)	1018 (3.5)
Bachelor's degree or higher, No. (%)	9277 (34.5)	7828 (34.9)	2487 (8.5)
Current smoker, No. (%)	7101 (25.0)	6023 (26.9)	1018 (3.5)
Enrolled during the COVID–19 lockdowns	4178 (14.3)	2706 (12.1)	159 (0.5)
Psoriasis duration, median (IQR), y	6 (2–14)	6 (2–14)	27 (0.1)
Family history, No. (%)	21 924 (16.5)	3816 (17.0)	3166 (10.8)
Psoriasis phenotype, No. (%)			
Plaque psoriasis	24 574 (83.6)	18 231 (81.3)	17 (0.1)
Erythrodermic psoriasis	376 (1.3)	242 (1.1)	
Pustular psoriasis	968 (3.3)	658 (2.9)	
Guttate psoriasis	3670 (12.5)	3016 (13.4)	
Psoriatic arthritis	2302 (7.8)	1590 (7.1)	
Lesions on special areas, No. (%)			
Nail involvement	6440 (23.1)	5365 (23.9)	1527 (5.2)
Scalp involvement	18 190 (64.0)	14 578 (65.0)	986 (3.4)
Palm or/and sole involvement	5705 (20.3)	4458 (19.9)	1288 (4.4)
Genital involvement	3702 (13.3)	3014 (13.4)	1544 (5.2)
Disease severity, median (IQR)			
PASI	7.2 (3.0–14.7)	7.2 (3.0–14.6)	507 (1.7)
BSA	10.0 (3.4–30.0)	10.0 (3.0–30.0)	494 (1.7)
IGA	3 (2–3)	3 (2–3)	500 (1.7)
DLQI	8 (3–13)	8 (3–12)	1 261 (4.3)
Comorbidities No. (%)	4101 (13.9)	3245 (14.5)	2630 (8.9)
Previous biological treatment <sup>c</sup> , No. (%)	2603 (8.9)	1982 (8.8)	23 (0.1)
Treatment demands			
Healing skin lesions rapidly	25 213 (88.8)	20 111 (89.7)	1021 (3.5)
Improving mental health	10 706 (37.7)	8531 (38.0)	
Reducing social discrimination	8854 (31.2)	7042 (31.4)	
Working and socializing normally	8120 (28.6)	6604 (29.4)	
Relieving painful/ burning feelings	6979 (24.6)	5476 (24.4)	
Relieving itchy feelings	10 668 (37.6)	8549 (38.1)	

**Table S2.** Comparison of baseline characteristics between full population and study population with complete data

**Full population** 

Study

Missing

Reducing side effects of treatment	8708 (30.7)	7162 (31.9)
Reducing relapses	1651 (5.8)	1063 (4.7)

Abbreviations: BMI, body mass index; PASI, Psoriasis Area and Severity Index; BSA, Body Surface Area; IGA, Investigator's Global

Assessment; DLQI, Dermatology Life Quality Index.

<sup>a</sup> Totally 29,412 adults were enrolled in the registry by September 2021.

<sup>b</sup> Unemployment rate was calculated in the working–age population, which excluded retired patients and students.

 $^\circ$ Biological treatment included Tumor Necrosis Factor- $\alpha$  Inhibitors and Interleukin Inhibitors.

	Reduc	ing socia	al	Workir	ng and		Relievi	ng painf	ul or	Relievi	ng itchy		Reduc	ing the s	ide	Reduc	ing relap	ses
	discrin	nination		sociali	zing nor	mally	burnin	g feeling	IS	feeling	S		effects	of treat	ment			
	Yes	No	Р	Yes	No	Ρ	Yes	No	Р	Yes	No	Р	Yes	No	Р	Yes	No	Р
	(n=70	(n=15	val	(n=66	(n=15	val	(n=54	(n=16	val	(n=85	(n=13	val	(n=71	(n=15	val	(n=10	(n=21	val
	42)	383)	ue	04)	821)	ue	76)	949)	ue	49)	876)	ue	62)	263)	ue	63)	362)	ue
Demographics																		
Male, n (%)	4664	9903	0.0	4438	10129	<0.	3631	10936	0.0	5506	9061	0.1	4557	10010	0.0	675	13892	0.3
	(66.2)	(64.4)	07	(67.2)	(64.0)	001	(66.3)	(64.5)	16	(64.4)	(65.3)	73	(63.6)	(65.6)	04	(63.5)	(65.0)	07
Age,y,median(I	40(31	40(31	0.1	38(30	41(31	<0.	43(32	39(31	<0.	41(32	39(31	<0.	40(31	40(31	0.9	39(30	40(31	0.1
QR)	-53)	-54)	21	-51)	-54)	001	-56)	-53)	001	-55)	-52)	001	-53)	-54)	35	-53)	-54)	42
BMI,kg/m <sup>2</sup> ,medi	24.1(	24.0(	0.6	24.2(	24.0(	<0.	24.1(	24.0(	0.1	24.2(	24.0(	0.0	24.2(	24.0(	0.0	23.4(	24.1(	<0.
an(IQR)	21.9–	21.6–	08	21.9–	21.7–	001	21.9–	21.7–	59	21.8–	21.7–	02	21.8–	21.7–	02	21.3–	21.8–	001
	26.7)	26.8)		27.0)	26.7)		26.7)	26.7)		27.0)	26.6)		27.0)	26.6)		26.0)	26.8)	
Unemployment <sup>a</sup> ,	658	1336	0.3	668	1326	0.0	575	1419	<0.	873	1121	<0.	740	1254	<0.	85	1909	0.6
n (%)	(11.7)	(11.2)	32	(12.4)	(11.0)	08	(13.8)	(10.7)	001	(13.4)	(10.2)	001	(13.0)	(10.6)	001	(10.4)	(11.5)	43
Married, n (%)	5486	11718	0.0	4915	12289	<0.	4419	12785	<0.	6666	10538	<0.	5560	11644	0.0	806	16398	0.4
	(77.9)	(76.2)	04	(74.4)	(77.7)	001	(80.7)	(75.4)	001	(78.0)	(75.9)	001	(77.6)	(76.3)	27	(75.8)	(76.8)	79
Bachelor's	2246	5582	<0.	2460	5368	<0.	1546	6282	<0.	2794	5034	<0.	2457	5371	0.1	380	7448	0.5
degree, n (%)	(31.9)	(36.3)	001	(37.3)	(33.9)	001	(28.2)	(37.1)	001	(32.7)	(36.3)	001	(34.3)	(35.2)	96	(35.8)	(34.9)	56
Current smoker,	1685	4338	<0.	1854	4169	0.0	1447	4576	0.4	2351	3672	0.0	1955	4068	0.3	259	5764	0.0
n (%)	(23.9)	(28.2)	001	(28.1)	(26.4)	08	(26.4)	(27.0)	05	(27.5)	(26.5)	89	(27.3)	(26.7)	10	(24.4)	(27.0)	60
COVID-19	889	1817	0.0	799	1907	0.9	647	2059	0.5	1051	1655	0.4	938	1768	0.0	344	2362	<0.
lockdown, n (%)	(12.6)	(11.8)	83	(12.1)	(12.1)	25	(11.8)	(12.1)	11	(12.3)	(11.9)	13	(13.1)	(11.6)	01	(32.4)	(11.1)	001
Duration,y,	8(2–	6(1–	<0.	8(2–	6(1–	<0.	7(2–	6(1–	<0.	6(2–	6(1–	0.9	7(2–	6(1–	<0.	6(2–	6(2-	0.8
median(IQR)	15)	14)	001	15)	14)	001	15)	14)	001	14)	14)	83	15)	14)	001	14)	14)	73
Continued																		

## **Table S3.** Baseline characteristics stratified by treatment demands

-	Reduci	ing socia	al	Workin	g and		Relievi	ng painf	ul or	Relievi	ng itchy		Reduc	ing the s	ide	Reducing relapses		
	discrin	nination		sociali	zing nor	mally	burnin	g feeling	S	feeling	S		effects	of treat	nent			
	Yes	No	Ρ	Yes	No	Ρ	Yes	No	Ρ	Yes	No	Р	Yes	No	Ρ	Yes	No	Р
	(n=70	(n=15	val	(n=66	(n=15	val	(n=54	(n=16	val	(n=85	(n=13	val	(n=71	(n=15	val	(n=10	(n=21	val
	42)	383)	ue	04)	821)	ue	76)	949)	ue	49)	876)	ue	62)	263)	ue	63)	362)	ue
Family history, n	1100	2716	<0.	1201	2615	0.0	862	2954	0.0	1458	2358	0.9	1324	2492	<0.	184	3632	0.7
(%)	(15.6)	(17.7)	001	(18.2)	(16.5)	03	(15.7)	(17.4)	04	(17.1)	(17.0)	06	(18.5)	(16.3)	001	(17.3)	(17.0)	95
Psoriasis phenor	type <sup>ь</sup> , n	(%)																
Plaque	5934	12297	<0.	5417	12814	0.0	4473	13758	0.3	7016	11215	0.0	5823	12408	0.9	929	17302	<0.
psoriasis	(84.3)	(79.9)	001	(82.0)	(81.0)	71	(81.7)	(81.2)	39	(82.1)	(80.8)	20	(81.3)	(81.3)	86	(87.4)	(81.0)	001
Erythrodermic	93	149	0.0	120	122	<0.	116	126	<0.	124	118	<0.	113	129	<0.	13	229	0.6
psoriasis	(1.32)	(0.97)	18	(1.8)	(0.77)	001	(2.1)	(0.7)	001	(1.5)	(0.9)	001	(1.6)	(0.8)	001	(1.2)	(1.1)	42
Pustular	184	474	0.0	156	502	0.0	230	428	<0.	250	408	0.9	189	469	0.0	25	633	0.2
psoriasis	(2.6)	(3.1)	54	(2.4)	(3.2)	01	(4.2)	(2.5)	001	(2.9)	(2.9)	45	(2.6)	(3.1)	73	(2.4)	(3.0)	49
Guttate	735	2281	<0.	809	2207	0.0	533	2483	<0.	1063	1953	<0.	934	2082	0.2	88	2928	<0.
psoriasis	(10.4)	(14.8)	001	(12.3)	(13.9)	01	(9.7)	(14.6)	001	(12.4)	(14.1)	001	(13.0)	(13.6)	20	(8.3)	(13.7)	001
Arthropathic	595	995	<0.	498	1092	0.0	606	984	<0.	631	959	0.1	536	1054	0.1	60	1530	0.0
psoriasis	(8.5)	(6.5)	001	(7.5)	(6.9)	89	(11.1)	(5.8)	001	(7.4)	(6.9)	83	(7.5)	(6.9)	16	(5.6)	(7.2)	60
Lesions on spec	ial areas	s, n (%)																
Nail	1701	3664	0.5	1943	3422	<0.	1548	3817	<0.	2280	3085	<0.	2019	3346	<0.	286	5079	0.0
involvement	(24.2)	(23.8)	83	(29.4)	(21.6)	001	(28.3)	(22.5)	001	(26.7)	(22.2)	001	(28.2)	(21.9)	001	(26.9)	(23.8)	20
Scalp	4538	10040	0.2	4662	9916	<0.	3693	10885	<0.	5937	8641	<0.	5011	9567	<0.	694	13884	0.8
involvement	(64.4)	(65.3)	29	(70.6)	(62.7)	001	(67.4)	(64.2)	001	(69.5)	(62.3)	001	(70.0)	(62.7)	001	(65.3)	(65.0)	45
Palmoplantar	1519	2939	<0.	1482	2976	<0.	1390	3068	<0.	1906	2552	<0.	1590	2868	<0.	209	4249	0.8
involvement	(21.6)	(19.1)	001	(22.4)	(18.8)	001	(25.4)	(18.1)	001	(22.3)	(18.4)	001	(22.2)	(18.8)	001	(19.7)	(19.9)	55

Continued

	Reducing social Working and			Relievi	ng painfi	ul or	Relievi	ng itchy		Reducing the side			Reducing relapses					
	discrim	ination		socializ	zing norr	nally	burning	g feeling	s	feeling	s		effects	of treatm	nent			
	Yes	No	Ρ	Yes	No	Ρ	Yes	No	Ρ	Yes	No	Ρ	Yes	No	Ρ	Yes	No	Ρ
	(n=70	(n=15	val	(n=66	(n=15	val	(n=54	(n=16	val	(n=85	(n=13	val	(n=71	(n=15	val	(n=10	(n=21	val
	42)	383)	ue	04)	821)	ue	76)	949)	ue	49)	876)	ue	62)	263)	ue	63)	362)	ue
Lesions on speci	ial areas	, n (%)																
Genital	1020	1994	0.0	1088	1926	<0.	936	2078	<0.	1403	1611	<0.	1186	1828	<0.	164	2850	0.0
involvement	(14.5)	(13.0)	02	(16.5)	(12.2)	001	(17.1)	(12.3)	001	(16.4)	(11.6)	001	(16.6)	(12.0)	001	(15.4)	(13.3)	52
Disease severity,	median	(IQR)																
PASI	9.6	6.0	<0.	9.0	6.4	<0.	9.2	6.4	<0.	7.9	6.6	<0.	8.1	6.5	<0.	5.8	7.2	<0.
	(4.2–	(2.7–	001	(3.7–	(2.8–	001	(3.9–	(2.8–	001	(3.3–	(2.8–	001	(3.6–	(2.8–	001	(2.6–	(3.0–	001
	17.4)	13.2)		17.1)	13.5)		18.0)	13.6)		16.1)	13.8)		16.1)	13.9)		12.0)	14.7)	
BSA, %	15.0	8.0	<0.	13.0	10.0	<0.	15.0	10.0	<0.	10.0	10.0	<0.	10.0	10.0	<0.	9.0	10.0	0.0
	(5.0–	(3.0–	001	(5.0–	(3.0–	001	(5.0–	(3.0–	001	(3.3–	(3.0–	001	(4.0–	(3.0–	001	(3.0–	(3.0–	86
	31.0)	25.0)		34.0)	25.0)		35.0)	25.0)		30.0)	27.0)		30.0)	27.0)		30.0)	30.0)	
IGA	3 (2–	2 (2–	<0.	3 (2–	3 (2–	<0.	3 (2–	3 (2–	<0.	3 (2–	3 (2–	<0.	3 (2–	3 (2–	<0.	3 (2–	3 (2–	<0.
	3)	3)	001	3)	3)	001	3)	3)	001	3)	3)	001	3)	3)	001	3)	3)	001
DLQI, median	10(6–	6(2–	<0.	10(6–	6(2–	<0.	10(6—	7(2–	<0.	9(4–	7(2–	<0.	9(4–	7(2–	<0.	8(3–	8(3–	0.1
(IQR)	16)	10)	001	17)	11)	001	16)	11)	001	14)	12)	001	15)	11)	001	12)	12)	94
Comorbidity <sup>c</sup> , n	906	2339	<0.	990	2255	0.0	872	2373	<0.	1404	1841	<0.	1158	2087	<0.	152	3093	0.8
(%)	(12.9)	(15.2)	001	(15.0)	(14.3)	03	(15.9)	(14.0)	001	(16.4)	(13.3)	001	(16.2)	(13.7)	001	(14.3)	(14.5)	90
Previous use of	631	1351	0.6	608	1374	0.2	414	1568	<0.	557	1425	<0.	597	1385	0.0	114	1868	0.0
biologics <sup>d</sup>	(9.0)	(8.8)	63	(9.2)	(8.7)	09	(7.6)	(9.3)	001	(6.5)	(10.3)	001	(8.3)	(9.1)	69	(10.7)	(8.7)	26

Abbreviations: BMI, body mass index; BSA, Body Surface Area; DLQI, Dermatology Life Quality Index; IGA, Investigator's Global Assessment; IQR, interquartile range; PASI, Psoriasis Area and

Severity Index.

<sup>a</sup>The unemployment rate was calculated in the working-age population, which excluded retired patients and students.

<sup>b</sup>Phenotypes were not mutually exclusive, thus the total percentage was higher than 100%.

°Comorbidity presented the existence of any disease conditions including cardiovascular diseases, respiratory diseases, kidney diseases, rheumatic diseases, digestive diseases, tumors, endocrine

diseases, etc.

 $^{\text{d}}\textsc{Biologics}$  included Tumor Necrosis Factor - $\alpha$  Inhibitors and Interleukin Inhibitors.

**Table S4.** Mutlivariable logistic regression models examining the impact of PASI on treatment demands stratified by COVID–19 lockdowns

Odds ratios (95% Cl)	Without	COVID-	19 lockd	lowns				With CO		Heterogeneity test					
	Mild	Modera	ate	Seve	re	Trend	Test <sup>a</sup>	Mild	Modera	ate	Seve	re	Trend Test	Q	Р
	PASI<3	PASI 3	to <10	PASI	≥10			PASI<3	PASI 3	to <10	PASI	≥10		(df)	value
Healing skin lesions	1.0	1.17	(1.03–	1.45	(1.27–	1.02	(1.01–	1.0	1.50	(1.12–	2.19	(1.57–	1.04 (1.02–	3.42	0.064
rapidly		1.32)*		1.65)	***	1.02)**	*		2.02)**		3.05)*	**	1.06)***	(1)	
Improving mental	1.0	1.47	(1.35–	2.21	(2.03–	1.03	(1.02–	1.0	1.75	(1.40–	2.82	(2.24–	1.04 (1.03–	3.44	0.064
health		1.59)***		2.40)	***	1.03)**	*		2.18)***		3.55)*	**	1.05)***	(1)	
Reducing social	1.0	1.65	(1.52–	2.51	(2.29–	1.03	(1.02–	1.0	2.46	(1.92–	4.35	(3.37–	1.05 (1.04–	12.82	<0.001
discrimination		1.81)***		2.74)	***	1.03)**	*		3.15)***		5.62)*	**	1.06)***	(1)	
Working and	1.0	1.27	(1.17–	1.63	(1.49–	1.02	(1.01–	1.0	1.70	(1.33–	2.81	(2.19–	1.03 (1.02–	9.09	0.003
socializing normally		1.39)***		1.78)	***	1.02)***			2.17)***		3.60)*	**	1.04)***	(1)	
Relieving painful or	1.0	1.22	(1.11–	1.59	(1.45–	1.02	(1.02–	1.0	1.70	(1.28–	2.66	(2.01–	1.04 (1.03–	9.74	0.002
burning feelings		1.34)***		1.75)	***	1.02)**	*		2.25)***		3.53)*	**	1.05)***	(1)	
Relieving itchy	1.0	1.07	(0.99–	1.11	(1.03–	1.01	(1.004–	1.0	1.32	(1.06–	1.69	(1.35–	1.02 (1.01–	8.27	0.004
feelings		1.16)		1.21)		1.01)**	*		1.63)*		2.11)*	**	1.03)***	(1)	
Reducing the side	1.0	1.25	(1.15–	1.32	(1.21–	1.01	(1.01–	1.0	1.66	(1.33–	1.90	(1.51–	1.02 (1.01–	2.44	0.118
effects of treatment		1.36)***		1.44)	***	1.01)**	*		2.07)***		2.40)*	**	1.03)***	(1)	
Reducing relapses	1.0	0.81	(0.67–	0.61	(0.49–	0.98	(0.98–	1.0	0.89	(0.66–	0.81	(0.58–	1.01 (0.997–	10.88	0.001
		0.97)*		0.75)	***	0.99)**	*		1.20)		1.12)		1.02)	(1)	

Abbreviations: PASI, Psoriasis Area and Severity Index. All the models adjusted for sex, age, BMI, marriage, education, smoke, disease course, family history, disease phenotype, whether special areas were affected, comorbidities, and previous treatment, stratified by whether was enrolled during the COVID pandemic.

<sup>a</sup>PASI was treated as a continuous variable in the trend test.

\*Significant at *P*<0.050; \*\*Significant at *P*<0.010; \*\*\*Significant at *P*<.001.

**Table S5.** Mutlivariable logistic regression models examining the impact of BSA on treatment demands stratified by COVID–19 lockdowns

Odds ratios (95%	Odds ratios (95% Without COVID-19 lockdowns						With COVID-19 lockdowns			
CI)								test		
	Mild	Moderate	Severe	Trend Test <sup>a</sup>	Mild	Moderate	Severe Trend Test	Q (df)	Ρ	
	BSA<3%	BSA 3 to <10%	BSA≥10%		BSA<3%	BSA 3 to <10%	BSA≥10%		value	
Healing skin lesions	1.0	1.10 (0.96–1.26)	1.33 (1.17–	1.01 (1.01–	1.0	1.25 (0.88–	1.38 (0.999– 1.01 (1.001–	0.19	0.663	
rapidly			1.50)***	1.01)***		1.76)	1.896) 1.01) <sup>*</sup>	(1)		
Improving mental	1.0	1.46 (1.33–	2.01 (1.85–	1.01 (1.01–	1.0	1.72 (1.33–	3.27 (2.57- 1.02 (1.01-	22.01	<0.001	
health		1.60)***	2.19)*** 1.01)***			2.23)***	4.15)*** 1.02)***	(1)		
Reducing social	1.0	1.64 (1.48–	2.32 (2.12–	1.01 (1.01–	1.0	1.87 (1.40–	4.56 (3.48– 1.02 (1.02–	37.08	<0.001	
discrimination		1.81)***	2.54)***	1.01)***		2.51)***	5.97)*** 1.03)***	(1)		
Working and	1.0	1.32 (1.19–	1.64 (1.50–	1.01 (1.01–	1.0	1.76 (1.32–	3.20 (2.45– 1.02 (1.01–	13.25	<0.001	
socializing normally		1.45)***	1.79)*** 1.01)***			2.35)***	4.18)*** 1.02)***	(1)		
Relieving painful or	1.0	1.28 (1.15–	1.70 (1.54–	1.01 (1.01–	1.0	1.78 (1.29–	2.62 (1.94- 1.01 (1.01-	3.84	0.050	
burning feelings		1.42)***	1.87)*** 1.01)***			2.45)***	3.54)*** 1.02)***	(1)		
Relieving itchy	1.0	0.98 (0.89–1.07)	1.07 (0.99–	1.001 (0.999–	1.0	1.10 (0.86–	1.41 (1.13– 1.01 (1.004–	11.34	0.001	
feelings			1.16)	1.002)		1.39)	1.76)** 1.01)***	(1)		
Reducing the side	1.0	1.15 (1.05–	1.26 (1.16–	1.003 (1.002–	1.0	1.50 (1.16–	1.99 (1.57– 1.01 (1.003–	3.66	0.056	
effects of treatment		1.26)**	1.37)*** 1.005)***			1.93)**	2.52)*** 1.01)***	1.01)*** (1)		
Reducing relapses	1.0	1.06 (0.85–1.32)	0.97 (0.79–	0.997 (0.99–	1.0	1.12 (0.81–	0.74 (0.54– 0.996 (0.99–	0.07	0.785	
			1.18)	1.001)		1.55)	1.02) 1.003)	(1)		

Abbreviations: BSA, Body Surface Area. All the models adjusted for sex, age, BMI, marriage, education, smoke, disease course, family history, disease phenotype, whether special areas were

affected, comorbidities, and previous treatment, stratified by whether was enrolled during the COVID pandemic.

<sup>a</sup>BSA was treated as a continuous variable in the trend test.

\*Significant at P<0.050; \*\*Significant at P<0.010; \*\*\*Significant at P<.001.

**Table S6.** Mutlivariable logistic regression models examining the impact of IGA on treatment demands stratified by COVID–19 lockdowns

Odds ratios (95% Cl)	Without COVID-19 lockdowns						With COVID-19 lockdowns					Heterogenei ty test	
	Almost	Mild	Moderate	Severe	Trend Test <sup>a</sup>	Almost	Mild	Moderate	Severe	Trend Test	Q	Р	
	clear	IGA=2	IGA=3	IGA=4		clear	IGA=2	IGA=3	IGA=4		(df)	value	
	IGA=0/1					IGA=0/1							
Healing skin	1.0	1.30 (1.12–	1.68 (1.44–	1.64 (1.35–	1.21 (1.14–	1.0	1.17 (0.82–	2.49 (1.71–	2.70 (1.63–	1.49 (1.30–	7.75	0.005	
lesions rapidly		1.52)**	1.96)***	1.99)***	1.27)***		1.67)	3.64)***	4.49)***	1.71)***	(1)		
Improving mental	1.0	1.22 (1.09–	1.70 (1.52–	2.21 (1.94–	1.30 (1.26–	1.0	1.28 (0.96–	2.07 (1.57–	1.91 (1.36–	1.30 (1.18–	<0.0	0.971	
health		1.36)***	1.90)***	2.51)***	1.35)***		1.70)	2.74)***	2.68)***	1.43)***	1 (1)		
Reducing social	1.0	1.43 (1.27–	1.85 (1.64–	2.55 (2.22–	1.32 (1.28–	1.0	1.48 (1.10–	2.04 (1.52–	2.08 (1.46–	1.29 (1.17–	0.21	0.646	
discrimination		1.61)***	2.08)***	2.92)***	1.37)***		2.01)*	2.75)***	2.97)***	1.43)***	(1)		
Working and	1.0	1.12 (0.99–	1.43 (1.27–	1.65 (1.45–	1.19 (1.14–	1.0	1.06 (0.78–	1.55 (1.16–	1.69 (1.19–	1.24 (1.12–	0.54	0.461	
socializing normally		1.26)	1.60)***	1.89)***	1.23)***		1.44)	2.09)**	2.41)**	1.37)***	(1)		
Relieving painful or	1.0	1.21 (1.06–	1.54 (1.36–	1.88 (1.62–	1.23 (1.18–	1.0	1.00 (0.69–	1.79 (1.27–	1.88 (1.26–	1.32 (1.18–	1.29	0.256	
burning feelings		1.38)**	1.76)***	2.18)***	1.28)***		1.44)	2.53)**	2.81)**	1.48)***	(1)		
Relieving itchy	1.0	1.21 (1.08–	1.45 (1.30–	1.61 (1.41–	1.17 (1.13–	1.0	1.04 (0.78–	1.53 (1.16–	1.16 (0.83–	1.13 (1.03–	0.38	0.539	
feelings		1.35)**	1.62)*** 1.83)***		1.21)***		1.37) 2.01)**		1.63) 1.24)*		(1)		
Reducing the side	1.0	1.09 (0.97–	1.28 (1.14–	1.25 (1.10–	1.09 (1.05–	1.0	1.08 (0.82–	1.30 (0.98–	0.96 (0.69–	1.02 (0.93–	1.37	0.241	
effects of treatment		1.22)	1.43)***	1.43)**	1.13)***		1.44)	1.71)	1.35)	1.13)	(1)		
Reducing relapses	1.0	0.63 (0.50–	0.53 (0.42–	0.52 (0.39–	0.79 (0.73–	1.0	0.83 (0.55–	1.29 (0.87–	0.48 (0.27–	0.98 (0.85–	5.86	0.016	
		0.79)***	0.67)***	0.70)***	0.87)***		1.27)	1.92)	0.85)*	1.13)	(1)		

Abbreviations: IGA, Investigator's Global Assessment. All the models adjusted for sex, age, BMI, marriage, education, smoke, disease course, family history, disease phenotype, whether special

areas were affected, comorbidities, and previous treatment, stratified by whether was enrolled during the COVID pandemic.

<sup>a</sup>IGA was treated as a continuous variable in the trend test.

\*Significant at P<0.050; \*\*Significant at P<0.010; \*\*\*Significant at P<.001